Gefitinib (ZD1839) is a potent, selective, reversible, and ATP-competitive EGFR inhibitor. It affects PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT signaling by binding to the ATP-binding pocket of the EGFR kinase domain to block autophosphorylation, effectively inhibiting cell proliferation, migration, and invasion, while inducing apoptosis.
Gefitinib (ZD1839) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Gefitinib (ZD1839) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.